Investigation of narciclasine’s role in dietary interventions for nonalcoholic fatty liver disease Effects on inflammation and lipid metabolism
Main Article Content
Keywords
Narciclasine, inflammation, fat accumulation, nonalcoholic fatty liver disease
Abstract
Nonalcoholic fatty liver disease (NAFLD), a condition caused by a buildup of fat in liver cells because of wrong choices and nutrition intake patterns over time, is a common chronic metabolic disorder among individuals today. Narciclasine (Nar), a compound present in Haemanthus coccineus L., has been noted for its strong anti-inflammatory effects. However, its impact on regulating metabolic imbalances associated with NAFLD requires further investigation. In this research investigation using mice with NAFLD induced by a high-fat diet (HFD) and a cell model stimulated with fatty acids (FFAs), the aim was to examine the impact of Nar on liver health outcomes. The findings indicated that Nar helped improve the changes in metabolic parameters caused by the HFD, such as metabolism and inflammatory markers. Moreover, the buildup of liver fat triggered by the HFD was lessened after Nar treatment. Similarly, the inflammatory reaction in liver tissues exacerbated by the HFD was notably reduced with the involvement of Nar. The results of lab tests showed that Nar stopped FFA, which effectively triggered production and cell death in liver cells. It was shown that Nar blocked the activation of the NF-κB signaling pathway, which plays a role in inflammation and metabolic imbalances. These discoveries indicate a potential for Nar as a supplement or treatment for handling NAFLD. It provides a method to cure patients by adjusting important metabolic and inflammatory routes.
References
Cobbina E. and Akhlaghi F. 2017. Non-alcoholic fatty liver disease (NAFLD)–pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab. Rev. 49(2):197–211. https://doi.org/10.1080/03602532.2017.1293683
Dietrich P. and Hellerbrand C. 2014. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract. Res. Clin. Gastroenterol. 28(4):637–653. https://doi.org/10.1016/j.bpg.2014.07.008
Duan Q., Jia Y., Qin Y., Jin,Y., Hu H. and Chen J. 2020. Narciclasine attenuates LPS-induced acute lung injury in neonatal rats through suppressing inflammation and oxidative stress. Bioengineered. 11(1):801–810. https://doi.org/10.1080/21655979.2020.1795424
Fürst R. 2016. Narciclasine–an amaryllidaceae alkaloid with potent antitumor and anti-inflammatory properties. Planta. Med. 82(16):1389–1394. https://doi.org/10.1055/s-0042-115034
Farzanegi P., Dana A., Ebrahimpoor Z., Asadi M. and Azarbayjani, M.A. 2019. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation. Eur. J. Sport Sci. 19(7):994–1003. https://doi.org/10.1080/17461391.2019.1571114
Gao W., Xu B., Zhang Y., Liu S., Duan Z., Chen Y. and Zhang, X. 2022. Baicalin attenuates oxidative stress in a tissue-engineered liver model of NAFLD by scavenging reactive oxygen species. Nutrients. 14(3). https://doi.org/10.3390/nu14030541
Gao X., Nan Y., Zhao Y., Yuan Y., Ren B., Sun C., et al. 2017. Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5. Biochim. Biophys. Acta. Mol. Cell Biol. Lipids. 1862(12):1512–1519. https://doi.org/10.1016/j.bbalip.2017.09.007
He G. and Karin M. 2011. NF-κB and STAT3–key players in liver inflammation and cancer. Cell Res. 21(1):159–168. https://doi.org/10.1038/cr.2010.183
Hu Y., Du G., Li G., Peng X., Zhang Z. and Zhai, Y. 2021. The miR-122 inhibition alleviates lipid accumulation and inflammation in NAFLD cell model. Arch. Physiol. Biochem. 127(5):385–389. https://doi.org/10.1080/13813455.2019.1640744
Julien S.G., Kim S.Y., Brunmeir R., Sinnakannu, J.R., Ge X., Li H., et al. 2017. Narciclasine attenuates diet-induced obesity by promoting oxidative metabolism in skeletal muscle. PLoS Biol. 15(2):e1002597. https://doi.org/10.1371/journal.pbio.1002597
Kang S.J., Park S.T., Ha G.C. and Ko, K.J.J.J.o.M.s. H. 2022. Association between cardiorespiratory fitness, muscle strength, and non-alcoholic fatty liver disease in middle-aged men. JOMH. 18(9):184.
Kingsley M.K., Bhat B.V., Badhe B.A., Dhas B.B. and Parija, S.C. 2020. Narciclasine improves outcome in sepsis among neonatal rats via inhibition of calprotectin and alleviating inflammatory responses. Sci. Rep. 10(1):2947. https://doi.org/10.1038/s41598-020-59716-7
Kong Y., Jiang J., Huang Y., Liu X., Jin Z., Li, L., et al. 2022. Narciclasine inhibits phospholipase A2 and regulates phospholipid metabolism to ameliorate psoriasis-like dermatitis. Front. Immunol. 13:1094375. https://doi.org/10.3389/fimmu.2022.1094375
Lawrence T. 2009. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 1(6):a001651. https://doi.org/10.1101/cshperspect.a001651
Maurice J. and Manousou P. 2018. Non-alcoholic fatty liver disease. Clin. Med. (Lond): 18(3): 245–250. https://doi.org/10.7861/clinmedicine.18-3-245
Pouwels S., Sakran N., Graham Y., Leal A., Pintar T., Yang W., et al. 2022. Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr. Disord. 22(1):63. https://doi.org/10.1186/s12902-022-00980-1
Powell E.E., Wong V.W. and Rinella M. (2021). Non-alcoholic fatty liver disease. Lancet. 397(10290):2212–2224. https://doi.org/10.1016/s0140-6736(20)32511-3
Tanaka S., Hikita H., Tatsumi T., Sakamori R., Nozaki Y., Sakane S., et al. (2016). Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice. Hepatology. 64(6): 1994–2014. https://doi.org/10.1002/hep.28820
Tang R., Jia L. Li Y., Zheng J. and Qi P. 2021. Narciclasine attenuates sepsis-induced myocardial injury by modulating autophagy. Aging (Albany NY). 13(11):15151–15163. https://doi.org/10.18632/aging.203078
Tian Y., Wang J., Qin X., Li S., Lan C. and Sun X. 2022. Narciclasine ameliorated T cell mediated acute liver injury through activating AMPK pathway. Cell Immunol. 382:104631. https://doi.org/10.1016/j.cellimm.2022.104631
Yang W., Yang M., Yao H., Ma Y., Ren X., Teng L., et al. 2020. Effects of shikonin from Zicao on high-fat diet-induced nonalcoholic fatty liver disease in rats. Pak. J. Pharm. Sci. 33(6): 2527–2533.
Zhang Z., Yuan Y., Hu L., Tang J., Meng Z., Dai L., et al. 2023. ANGPTL8 accelerates liver fibrosis mediated by HFD-induced inflammatory activity via LILRB2/ERK signaling pathways. J. Adv. Res. 47:41–56. https://doi.org/10.1016/j.jare.2022.08.006
Zhao D., Zhang L.J., Huang T.Q., Kim J., Gu M.Y. and Yang H.O. 2021. Narciclasine inhibits LPS-induced neuroinflammation by modulating the Akt/IKK/NF-κB and JNK signaling pathways. Phytomedicine. 85:153540. https://doi.org/10.1016/j.phymed.2021.153540
Zhao N., Zhang X., Ding J., Pan Q., Zheng M.H., Liu W.Y., et al. 2022. SEMA7AR148W mutation promotes lipid accumulation and NAFLD progression via increased localization on the hepatocyte surface. JCI Insight. 7(15). https://doi.org/10.1172/jci.insight.154113
Zhou T., Cao L., Du Y., Qin L., Lu Y., Zhang Q., et al. (2023). Gypenosides ameliorate high-fat diet-induced nonalcoholic fatty liver disease in mice by regulating lipid metabolism. PeerJ. 11:e15225. https://doi.org/10.7717/peerj.15225
Zhu W., Sahar N.E., Javaid H.M.A., Pak E.S., Liang G., Wang Y., et al. 2021. Exercise-induced irisin decreases inflammation and improves NAFLD by competitive binding with MD2. Cells. 10(12):3306. https://doi.org/10.3390/cells10123306
Zhu X., Bian H., Wang L., Sun X., Xu X., Yan H., et al. 2019. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic. Biol. Med. 141:192–204. https://doi.org/10.1016/j.freeradbiomed.2019.06.019
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright Agreement with Authors
Before publication, after the acceptance of the manuscript, Authors have to sign a Publication Agreement with "Italian Journal of Food Science", granting and assigning to "Italian Journal of Food Science" the perpetual right to distribute the work free of charge by any means and in any parts of the world, including the communication to the public through the journal website.
License for Published Contents
http://creativecommons.org/licenses/by-nc-nd/4.0/